Coffina. I am joined today by Damien Conover , who is the director of our health ..... Damien, thanks for joining me. Damien Conover : Matt, thanks for having me ..... Great. Thanks for joining me, Damien . Conover : Matt, thanks for having me
will be partially tempered by patent exposures in the company’s pharmaceutical franchises. Morningstar analyst Damien Conover notes that Johnson & Johnson stands alone as a leader across the major health-care industries. He sees the company
New products will secure the drug firm’s wide moat and help increase the firm’s valuation over time, writes Morningstar’s Damien Conover .
Johnson also reported. They had a steady quarter, but not perhaps without any bumps at all. Glaser: Our analyst Damien Conover described it as steady. It was driven by the drug business; pharmaceuticals are really driving [TICKER:JNJ
paying a pretty decent premium to acquire [TICKER:HSP] Hospira (HSP). What's our take on that deal? Glaser: Damien Conover , our Pfizer analyst, thinks that it's going to be a good one for the pharmaceutical giant. They're spending
portfolio adjustments in anticipation of it. Morningstar's director of healthcare equity research and equity strategy, Damien Conover , who covers a number of pharmaceutical firms that use sophisticated tax-management strategies, said that Obama
The pharmaceutical giant turned in an in line fourth-quarter, but new competition and a strong dollar will slow growth in 2015, writes Morningstar’s Damien Conover .
the long-term trend of higher and higher prices had been broken. According to Morningstar healthcare team leader Damien Conover , a combination of higher prices from the consolidated generics industry, fewer drugs going off patent, and more
Coffina. I'm joined today by Damien Conover , who is the director of our health ..... Damien, thanks for joining me. Damien Conover : Matt, thanks for having me ..... Coffina: Thanks for joining me, Damien . Conover : Matt, thanks for having me
acquiring Cubist. What's our take on the deal? Glaser: Merck is going to spend $9.5 billion for Cubist, and Damien Conover , our health-care analyst, thinks this is about expanding Merck's presence into the hospital acute-care segment